Buscar
RenovoRx Inc
RNXTAñadir a la lista de seguimiento
0.920USD
-0.035-3.67%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
41.45MCap. mercado
PérdidaP/E TTM
Más Datos de RenovoRx Inc Compañía
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Información de RenovoRx Inc
Símbolo de cotizaciónRNXT
Nombre de la empresaRenovoRx Inc
Fecha de salida a bolsaAug 17, 2021
Director ejecutivoBagai (Shaun R)
Número de empleados10
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 17
Dirección2570 W. El Camino Real, Ste. 320,
CiudadMOUNTAIN VIEW
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94040
Teléfono14088002649
Sitio Webhttps://renovorx.com/
Símbolo de cotizaciónRNXT
Fecha de salida a bolsaAug 17, 2021
Director ejecutivoBagai (Shaun R)
Ejecutivos de RenovoRx Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de RenovoRx Inc?
Los cinco principales accionistas de RenovoRx Inc son: Ms. Kirsten Angela Macfarlane
¿Cuántas instituciones poseen acciones de RenovoRx Inc (RNXT)?
A fecha de 2026Q1, 54 instituciones poseen acciones de RenovoRx Inc, con un valor de mercado combinado de aproximadamente 9.02M, lo que representa el 20.02% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -632533.00.